|
| Index | - | P/E | - | EPS (ttm) | -2.84 | Insider Own | 0.20% | Shs Outstand | 29.63M | Perf Week | 20.99% |
| Market Cap | 111.55M | Forward P/E | - | EPS next Y | -0.03 | Insider Trans | - | Shs Float | 29.04M | Perf Month | -32.95% |
| Income | -83.90M | PEG | - | EPS next Q | -0.06 | Inst Own | 88.60% | Short Float / Ratio | 1.83% / 0.63 | Perf Quarter | -45.37% |
| Sales | 182.90M | P/S | 0.61 | EPS this Y | -560.00% | Inst Trans | -1.89% | Short Interest | 0.53M | Perf Half Y | -57.54% |
| Book/sh | 2.50 | P/B | 1.51 | EPS next Y | 94.20% | ROA | -31.50% | Target Price | 8.00 | Perf Year | -66.94% |
| Cash/sh | 0.23 | P/C | 16.40 | EPS next 5Y | 10.00% | ROE | -93.10% | 52W Range | 1.52 - 11.95 | Perf YTD | -41.74% |
| Dividend | - | P/FCF | - | EPS past 5Y | -51.30% | ROI | -22.70% | 52W High | -68.42% | Beta | 1.16 |
| Dividend % | - | Quick Ratio | 0.30 | Sales past 5Y | -16.90% | Gross Margin | 21.10% | 52W Low | 148.36% | ATR | 0.52 |
| Employees | 689 | Current Ratio | 0.60 | Sales Q/Q | -10.80% | Oper. Margin | -41.20% | RSI (14) | 43.57 | Volatility | 9.88% 19.04% |
| Optionable | Yes | Debt/Eq | 1.98 | EPS Q/Q | -392.70% | Profit Margin | -49.50% | Rel Volume | 0.58 | Prev Close | 3.79 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 839.21K | Price | 3.78 |
| Recom | 2.00 | SMA20 | -8.31% | SMA50 | -29.65% | SMA200 | -53.76% | Volume | 485,184 | Change | -0.40% |
 | ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
| Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California. | ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite